CSL Limited

10 days ago · seekingalpha.com

CSL Limited (CSLLY) Shareholder/Analyst Call Transcript

16 days ago · prnewswire.com

MELBOURNE, Australia, Oct. 21, 2026 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed Deborah Waterhouse as Chief Executive Officer and Managing Director of CSL from 1 February 2027. The appointment was made following an extensive global search process conducted by CSL's Board of Directors.

16 days ago · reuters.com

Oct 21 (Reuters) - Australia's CSL (CSL.

1 month ago · zacks.com

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?

1 month ago · prnewswire.com

/PRNewswire/ -- CSL y Alentis Therapeutics han anunciado hoy la firma de un acuerdo de colaboración global exclusiva para desarrollar y promocionar

1 month ago · proactiveinvestors.com

CSL Limited (ASX:CSL) has secured an exclusive licensing agreement with Swiss biotechnology company Alentis Therapeutics to develop and commercialise lixudebart, an experimental treatment targeting rare kidney and liver diseases. The deal gives CSL rights to advance the drug, which is currently in Phase 2 trials for ANCA-associated vasculitis, a rare autoimmune disease that can cause severe kidney damage.

1 month ago · reuters.com

Australia's CSL said on Monday it had entered ​into an agreement with Switzerland-based Alentis Therapeutics to ‌co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion before development ​funding.

1 month ago · prnewswire.com

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class therapy targeting claudin-1 across a range of kidney, liver and other diseases. Lixudebart is currently being evaluated in the ongoing Phase 2 RENAL trial in patients with ANCA (antineutrophil cytoplasmic antibodies)-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), a rare and potentially life-threatening autoimmune disease that can cause irreversible kidney damage and end-stage renal disease.

1 month ago · reuters.com

Australian biotechnology firm CSL said on Tuesday it is collaborating with Amazon's cloud ​arm to harness AI and cloud ‌technology across its research and clinical development pipeline.

2 months ago · prnewswire.com

Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine. MAIDENHEAD, United Kingdom, Sept.